Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
Corresponding Author
Sid E. O'Bryant
Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA
Corresponding author. Tel.: +1-817-735-2963; Fax: +1-817-735-0628.
E-mail address: [email protected]
Search for more papers by this authorMichelle M. Mielke
Department of Neurology, Mayo Clinic, Rochester, MN, USA
Department of Health Science Research, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRobert A. Rissman
Alzheimer's Disease Cooperative Study, Department of Neurosciences, UCSD School of Medicine, La Jolla, CA, USA
Search for more papers by this authorSimone Lista
AXA Research Fund and UPMC Chair, Paris, France
Department de Neurologie, Institut de la Memorie et de la Maladie d'Alzheimer (IM2A) et Institut du Cerveau et du la Moelle epiniere (ICM), Hospital de la Pitie-Salpetriere, Sorbonne Universites, Universite Pierre et Marie Curie, Paris, France
Search for more papers by this authorHenrik Zetterberg
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gotenburg, Molndal, Sweden
UCL Institute of Neurology, London, UK
Search for more papers by this authorPiotr Lewczuk
Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland
Search for more papers by this authorJames Hall
Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA
Search for more papers by this authorLeigh Johnson
Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA
Search for more papers by this authorYiu-Lian Fong
Johnson & Johnson, London Innovation Center, London, UK
Search for more papers by this authorJohan Luthman
Neuroscience Clinical Development, Clinical Neuroscience Eisai, Woodcliff Lake, NJ, USA
Search for more papers by this authorRichard Batrla-Utermann
Roche Diagnostics International Ltd., Rotkreuz, Switzerland
Search for more papers by this authorAlcibiades Villarreal
Centro de Neurociencias y Unidad de Investigacion Clinica, Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia (INDICASAT AIP), Ciudad del Saber, Panama, Panama
Search for more papers by this authorGabrielle Britton
Centro de Neurociencias y Unidad de Investigacion Clinica, Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia (INDICASAT AIP), Ciudad del Saber, Panama, Panama
Search for more papers by this authorPeter J. Snyder
Department of Neurology, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, USA
Search for more papers by this authorKim Henriksen
Neurodegenerative Diseases, Nordic Bioscience Biomarkers and Research, Herlev, Denmark
Search for more papers by this authorPaula Grammas
George and Anne Ryan Institute for Neuroscience, University of Rhode Island, RI, USA
Search for more papers by this authorVeer Gupta
Faculty of Health, Engineering and Sciences, Center of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia
Search for more papers by this authorRalph Martins
Faculty of Health, Engineering and Sciences, Center of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia
Search for more papers by this authorHarald Hampel
AXA Research Fund and UPMC Chair, Paris, France
Department de Neurologie, Institut de la Memorie et de la Maladie d'Alzheimer (IM2A) et Institut du Cerveau et du la Moelle epiniere (ICM), Hospital de la Pitie-Salpetriere, Sorbonne Universites, Universite Pierre et Marie Curie, Paris, France
Search for more papers by this authorBiofluid Based Biomarker Professional Interest Area
Search for more papers by this authorCorresponding Author
Sid E. O'Bryant
Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA
Corresponding author. Tel.: +1-817-735-2963; Fax: +1-817-735-0628.
E-mail address: [email protected]
Search for more papers by this authorMichelle M. Mielke
Department of Neurology, Mayo Clinic, Rochester, MN, USA
Department of Health Science Research, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRobert A. Rissman
Alzheimer's Disease Cooperative Study, Department of Neurosciences, UCSD School of Medicine, La Jolla, CA, USA
Search for more papers by this authorSimone Lista
AXA Research Fund and UPMC Chair, Paris, France
Department de Neurologie, Institut de la Memorie et de la Maladie d'Alzheimer (IM2A) et Institut du Cerveau et du la Moelle epiniere (ICM), Hospital de la Pitie-Salpetriere, Sorbonne Universites, Universite Pierre et Marie Curie, Paris, France
Search for more papers by this authorHenrik Zetterberg
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gotenburg, Molndal, Sweden
UCL Institute of Neurology, London, UK
Search for more papers by this authorPiotr Lewczuk
Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland
Search for more papers by this authorJames Hall
Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA
Search for more papers by this authorLeigh Johnson
Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA
Search for more papers by this authorYiu-Lian Fong
Johnson & Johnson, London Innovation Center, London, UK
Search for more papers by this authorJohan Luthman
Neuroscience Clinical Development, Clinical Neuroscience Eisai, Woodcliff Lake, NJ, USA
Search for more papers by this authorRichard Batrla-Utermann
Roche Diagnostics International Ltd., Rotkreuz, Switzerland
Search for more papers by this authorAlcibiades Villarreal
Centro de Neurociencias y Unidad de Investigacion Clinica, Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia (INDICASAT AIP), Ciudad del Saber, Panama, Panama
Search for more papers by this authorGabrielle Britton
Centro de Neurociencias y Unidad de Investigacion Clinica, Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia (INDICASAT AIP), Ciudad del Saber, Panama, Panama
Search for more papers by this authorPeter J. Snyder
Department of Neurology, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, USA
Search for more papers by this authorKim Henriksen
Neurodegenerative Diseases, Nordic Bioscience Biomarkers and Research, Herlev, Denmark
Search for more papers by this authorPaula Grammas
George and Anne Ryan Institute for Neuroscience, University of Rhode Island, RI, USA
Search for more papers by this authorVeer Gupta
Faculty of Health, Engineering and Sciences, Center of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia
Search for more papers by this authorRalph Martins
Faculty of Health, Engineering and Sciences, Center of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia
Search for more papers by this authorHarald Hampel
AXA Research Fund and UPMC Chair, Paris, France
Department de Neurologie, Institut de la Memorie et de la Maladie d'Alzheimer (IM2A) et Institut du Cerveau et du la Moelle epiniere (ICM), Hospital de la Pitie-Salpetriere, Sorbonne Universites, Universite Pierre et Marie Curie, Paris, France
Search for more papers by this authorBiofluid Based Biomarker Professional Interest Area
Search for more papers by this authorAbstract
The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.
References
- 1Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 2014; 10: 109–114
- 2Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 2014; 10: 115–131
- 3O'Bryant SE. Introduction to special issue on advances in blood-based biomarkers of Alzheimer's disease. Alzheimers Dement (Amst). 2016; 3: 110–112
10.1016/j.dadm.2016.06.003 Google Scholar
- 4Lista S, Faltraco F, Prvulovic D, Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol. 2013; 101–102 1–17
- 5O'Bryant SE, Edwards M, Johnson LA, Hall JA, Villarreal AE, Britton GB, et al. A blood screening test for Alzheimer's disease. Alzheimers Dement (Amst). 2016; 3: 83–90
- 6Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther. 2009; 15: 358–374
- 7Laske C, Sohrabi HR, Frost SM, Lopez-De-Ipina, Garrard P, Buscema M, et al. Innovative diagnostic tools for early detection of Alzheimer's disease. Alzheimers Dement. 2015; 11: 561–578
- 8O'Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, et al. Guidelines for the standardization fo preanalytic variables for blood-based biomarker studies in Alzheimer's disease. Alzheimers Dement. 2015; 11: 549–560
- 9O'Bryant SE, Lista S, Rissman RA, Edwards M, Zhang F, Hall J, et al. Comparing biological markers of Alzheimer's disease across blood fraction and platforms: comparing apples to oranges. Alzheimers Dement (Amst). 2016; 3: 27–34
- 10Vanderstichele HM, Shaw L, Vandijck M, Jeromin A, Zetterberg H, Blennow K, et al. Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard. Clin Chem. 2013; 59: 710–712
- 11Andreasson U, Blennow K, Zetterberg H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement (Amst). 2016; 3: 98–102
- 12Bowsher RR, Nowatzke W, Sailstad JM, Khan MU. Application of commercial research-grade biomarker assays in drug development: is it time to create ‘pharmaceutical-grade’ kits?. Bioanalysis. 2012; 4: 2427–2430
- 13Bowsher RR, Sailstad JM. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand. J Pharm Biomed Anal. 2008; 48: 1282–1289
- 14Blennow K, deMeyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, et al. Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging. 2009; 13: 205–208
- 15Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2010; 31: 357–367
- 16Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, et al. Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers Dement. 2015; 11: 249–257.e1
- 17Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20: 415–418
- 18Casanova R, Varma S, Simpson B, Kim M, An Y, Saldana S, et al. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement. 2016; 12: 815–822
- 19Li D, Misialek J, Boerwinkle E, Gottesman RF, Sharrett AR, Mosley TH, et al. Plasma phospholipids and prevalence of mild cognitive impairment/dementia in the ARIC Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst). 2016; 3: 73–82
10.1016/j.dadm.2016.02.008 Google Scholar
- 20Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement. 2014; 10: 799–807.e2
- 21Malm T, Loppi S, Kanninen KM. Exosomes in Alzheimer's disease. Neurochem Int. 2016; 97: 193–199
- 22Kanninen KM, Bister N, Koistinaho J, Malm T. Exosomes as new diagnostic tools in CNS diseases. Biochim Biophys Acta. 2016; 1862: 403–410
- 23Stern RA, Tripodis Y, Baugh CM, Fritts NG, Martin BM, Chaisson C, et al. Preliminary study of plasma exosomal tau as a potential biomarker for chronic traumatic encephalopathy. J Alzheimers Dis. 2016; 51: 1099–1109
- 24Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, et al. Prediction of conversion from mild cognitive impairment to dementia with neuronally-derived blood exosome protein profile. Alzheimers Dement (Amst). 2016; 3: 63–72
- 25Weinstein G, Beiser AS, Preis SR, Courchesne P, Chouraki V, Levy D, et al. Plasma clusterin levels and risk of demenita, Alzheimer's disease and stroke. Alzheimers Dement (Amst). 2016; 3: 103–109
10.1016/j.dadm.2016.06.005 Google Scholar
- 26Chang KA, Shin KY, Nam E, Lee YB, Moon C, Suh YH, Lee SH. Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer's disease. Neurochem Int. 2016; 97: 1–7
10.1016/j.neuint.2016.04.012 Google Scholar
- 27Blasko I, Kemmler G, Jungwirth S, Wichart I, Krampla W, Weissgram S, et al. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am J Geriatr Psychiatry. 2010; 18: 973–982
- 28Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15: 673–684
- 29Dage JL, Wennberg AM, Airey DC, Hagen CE, Knopman DS, Machulda MM, et al. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement2016 10.1016/j.jalz.2016.06.001
- 30Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, Hansson O, et al. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther. 2013; 5: 9
- 31Gisslen M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) as a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016; 3: 135–140
- 32Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016; 91: 494–496
- 33Gupta VB, Doecke JD, Hone E, Pedrini S, Laws SM, Thambissetty M, et al. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimers Dement (Amst). 2016; 3: 18–26
- 34Nagele E, Han M, DeMarshall C, Belinka B, Nagele R, et al. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One. 2011; 6: e23112
- 35DeMarshall CA, Han M, Nagele EP, Sarkar A, Acharya NK, Godsey, et al. Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease. Immunol Lett. 2015; 168: 80–88
10.1016/j.imlet.2015.09.010 Google Scholar
- 36DeMarshall CA, Nagele EP, Sarkar A, Acharya NK, Godsey G, Goldwaser EL, et al. Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement (Amst). 2016; 3: 51–62
10.1016/j.dadm.2016.03.002 Google Scholar
- 37Savica R, Murray ME, Persson XM, Kantarci K, Parisi JE, Dickson DW, et al. Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology. Alzheimers Dement (Amst). 2016; 3: 43–50
- 38O'Bryant SE, Xiao G, Zhang F, Edwards M, German DC, Yin X, et al. Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues. J Alzheimers Dis. 2014; 42: 1325–1335
- 39Gold LS, Klein G, Carr L, Kessler L, Sullivan SD, et al. The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines. Cancer Imaging. 2012; 12: 13–24
- 40Westwood S, Leoni E, Hye A, Lynham S, Khondoker MR, Ashton NJ, et al. Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. J Alzheimers Dis. 2016; 52: 561–572
- 41Tzen KY, Yang SY, Chen TF, Cheng TW, Horng HE, Wen HP, et al. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. ACS Chem Neurosci. 2014; 5: 830–836
- 42Kaneko N, Nakamura A, Washimi Y, Kato T, Sakurai T, Arahata Y, et al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci. 2014; 90: 353–364
- 43Burnham SC, Faux NG, Wilson W, Laws SM, Aimes D, Bedo J, et al. A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry. 2014; 19: 519–526
- 44Swaminathan S, Risacher SL, Yoder KK, West JD, Shen L, Kim S, et al. Association of plasma and cortical amyloid beta is modulated by APOE ε4 status. Alzheimers Dement. 2014; 10: e9–e18
- 45Van Gool SW, De Meyer G, Van De Voorde A, Vanmechelen E, Vanderstichele H, et al. Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. Neurotoxicology. 2004; 25: 471–480
- 46Van Gool SW, Van Kerschaver E, Brock P, Pottel H, Hulstaert F, Vanmechelen E, et al. Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. Leukemia. 2000; 14: 2076–2084
- 47Serban MA. Translational biomaterials—the journey from the bench to the market—think ‘product’. Curr Opin Biotechnol. 2016; 40: 31–34
- 48Tralau-Stewart CJ, Wyatt CA, Kleyn DE, Ayad A, et al. Drug discovery: new models for industry–academic partnerships. Drug Discov Today. 2009; 14: 95–101
- 49Ioannidis JP. Why most published research findings are false. PLoS Med. 2005; 2: e124
- 50Collins FS, Tabak LA. NIH plans to enhance reproducibility. Nature. 2014; 505: 612–613
- 51 Trouble at the lab, in The Economist. 2013.
- 52Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov. 2011; 10: 712–713
- 53Regelado A. Merk wants its money back if university research is wrong. 2016; MIT Technology Review
- 54Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis. 2014; 38: 515–531
- 55Soares HD, Chen Y, Sabbagh M, Rohrer A, Schrijvers E, Breteler M. Identifying early markers of alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci. 2009; 1180: 56–67
- 56 Group, F.-N.B.W. BEST (Biomarkers, EndpointS, and other Tools) resource. 2016; Food and Drug Administration/National Institutes of Health
- 57 Biomarker Development Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69: 89–95
- 58Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006; 23: 312–328
- 59 Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2012; 8: 1–72
10.1016/j.jalz.2011.10.007 Google Scholar
- 60 The Gerontological Society of American Workgroup on Cognitive Impairment Detection: report and recommendations. 2015
- 61Lundquist TS, Ready RE. Screening for Alzheimer's disease: inspiration and ideas from breast cancer strategies. J Appl Gerontol. 2015; 34: 317–328
10.1177/0733464813500711 Google Scholar
- 62Mattsson N, Carrillo MC, Dean RA, Devous MD, Nikolcheva T, Pesini P, et al. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst). 2015; 1: 412–419
- 63Quintard H, Leduc S, Ferrari P, Petit I, Ichai C, et al. Early and persistent high level of PS 100β is associated with increased poor neurological outcome in patients with SAH: is there a PS 100β threshold for SAH prognosis?. Crit Care. 2016; 20: 33
- 64Winterhoff B, Fryer L, Hammond E, Giri S, Mondal S, Roy D, et al. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur J Cancer. 2015; 51: 879–892
10.1016/j.ejca.2015.02.007 Google Scholar
- 65Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SKL, Dent RA, et al. Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat. 2014; 146: 153–162
- 66Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, et al. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer—a randomized biomarker pilot study. Clin Cancer Res. 2013; 19: 2755–2765
- 67Cohen AF, Burggraaf J, VanGerven JMA, Moerland M, Groeneveld GJ. The use of biomarkers in human pharmacology (Phase I) studies. Annu Rev Pharmacol Toxicol. 2015; 55: 55–74
- 68Hampel H, O'Bryant BS, Castrillo JI, Ritchie C, Rojkova K, Benda N, et al. Precision medicine: the golden gate for detection, treatment and prevention of Alzheimer's disease. J Prev Alzheimers Dis2016, in press
Citing Literature
